Pharming Group N.V.

Total Valuation

Pharming Group N.V. carries a market capitalization of 666.38M, placing it among publicly traded companies globally. Its enterprise value stands at 8.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pharming Group N.V. currently has 707.78M shares outstanding.

Valuation Ratios

Pharming Group N.V. trades at a trailing price-to-earnings ratio of 92.25. The price-to-sales ratio is 2.33, and the price-to-book ratio stands at 31.81.

Enterprise Valuation

On an enterprise value basis, Pharming Group N.V. trades at an EV/EBITDA multiple of 350.28 and an EV/FCF ratio of 196.15. The EV/Sales ratio of 23.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 693.02 provides insight into valuation relative to core operating earnings.

Financial Position

Pharming Group N.V. maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.89, indicating elevated leverage, while an interest coverage ratio of 1.66 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Pharming Group N.V. posts a return on equity of 3.64 and a return on invested capital of 1.92.

Taxes

Over the trailing twelve months, Pharming Group N.V. has paid 6.57M in income taxes, reflecting an effective tax rate of 41.47.

Stock Price Statistics

Pharming Group N.V.'s stock has declined approximately -33.74384% over the past 52 weeks. The 50-day moving average sits at 10.81, while the 200-day moving average is 14.07.

Income Statement

Over the trailing twelve months, Pharming Group N.V. generated 366.45M in revenue and converted that into 9.27M in net income, yielding earnings per share of 0.12. EBITDA reached 24.44M, while operating income came in at 12.35M.

Balance Sheet

Pharming Group N.V. holds 158.28M in cash and equivalents against 113.30M in total debt, resulting in a net debt position of -60.41M. Total book value stands at 270.49M, with working capital of 187.44M providing operational flexibility.

Cash Flow

Pharming Group N.V. produced 35.03M in operating cash flow over the past twelve months.

Margins

Pharming Group N.V. operates with a gross margin of 86.53, reflecting its pricing power and cost economics. The operating margin of 3.37 and net profit margin of 2.53 provide insight into operational efficiency.

Dividends & Yields

Scores

Pharming Group N.V. posts an Altman Z-Score of 26.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.